AstraZeneca PLC closed 21.95% short of its 52-week high of £133.88, which the company reached on September 3rd.

This was the ADR's fourth consecutive day of gains.

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Johnson Investment Counsel Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 4.4% during the first quarter, HoldingsChannel reports. The institutional investor ...

AstraZeneca has launched a Phase I clinical study titled An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...